• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Parasite-activated immunity may be able to suppress arthritis

June 8, 2016
By John Fox
HONG KONG – The findings of a new collaborative study by Chinese and German scientists suggest that activation in mice of a specific type of immune response, known as a Type 2 (Th2) response, using parasitic worm-derived stimuli, could clear the way to the development of new treatments for rheumatoid arthritis (RA).
Read More

Combination may induce necroptosis to treat AML

May 25, 2016
By John Fox
HONG KONG – The in vivo antileukemic efficacy and safety of a novel combination of apoptosis-regulating drugs seen in a recent study by Australian researchers suggests that inhibition of apoptosis and activation of another type of cell death, necroptosis, warrants clinical investigation as a treatment for acute myeloid leukemia (AML).
Read More

Combination may induce necroptosis to treat AML

May 24, 2016
By John Fox
HONG KONG – The in vivo antileukemic efficacy and safety of a novel combination of apoptosis-regulating drugs seen in a recent study by Australian researchers suggests that inhibition of apoptosis and activation of another type of cell death, necroptosis, warrants clinical investigation as a treatment for acute myeloid leukemia (AML).
Read More

Cancer drug stimulates stem cells, wound healing

May 18, 2016
By John Fox
HONG KONG – A new study has demonstrated for the first time that nanomolar concentrations of a candidate cancer compound may also have therapeutic value in the field of stem cell therapy and tissue regeneration, Chinese researchers reported in the May 9, 2016, early online edition of Proceedings of the National Academy of Sciences.
Read More

Cancer drug stimulates stem cells, wound healing

May 17, 2016
By John Fox
HONG KONG – A new study has demonstrated for the first time that nanomolar concentrations of a candidate cancer compound may also have therapeutic value in the field of stem cell therapy and tissue regeneration, Chinese researchers reported in the May 9, 2016, early online edition of Proceedings of the National Academy of Sciences.
Read More

New therapeutic target identified against glioblastoma

May 11, 2016
By John Fox
HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease.
Read More

New therapeutic target identified against glioblastoma

May 9, 2016
By John Fox
HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease.
Read More

Study identifies new therapeutic target for AMD

May 4, 2016
By John Fox
HONG KONG – A recent study by scientists at the Department of Ophthalmology and Visual Sciences of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has identified a potential new therapeutic target for age-related macular degeneration (AMD), which is the leading cause of central vision loss in the elderly.
Read More

Study identifies new therapeutic target for AMD

May 4, 2016
By John Fox
HONG KONG – A recent study by scientists at the Department of Ophthalmology and Visual Sciences of the Faculty of Medicine at the Chinese University of Hong Kong (CUHK) has identified a potential new therapeutic target for age-related macular degeneration (AMD), which is the leading cause of central vision loss in the elderly.
Read More

Crystal structure of key Zika viral protein reported

April 27, 2016
By John Fox
HONG KONG — Elucidation of the molecular structure of nonstructural protein 1 (NS1) from the Zika virus by Chinese Academy of Sciences (CAS) researchers shows that NS1 is involved in viral pathogenesis, a finding that could lead to new diagnostic technologies and treatments, including for related pathogens such as dengue and West Nile viruses.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe